Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | MGLL | Q99685 | 7/20 | 0.47 |
| ▸ | FAAH | O00519 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9674486 | 0.88 | PTGS1 (0.39) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL29810264 | 0.79 | GSK3A (0.38) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL27983508 | 0.78 | PRKCA (0.46) | FAAHALDH1A1HPGDHSP90AA1LMNA | |
| SCHEMBL1935917 | 0.78 | PRKCA (0.46) | FAAHALDH1A1HPGDHSP90AA1LMNA | |
| SCHEMBL949470 | 0.77 | MGLL (0.50) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL6910643 | 0.77 | PTGS1 (0.51) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL27309683 | 0.76 | PRKCA (0.43) | FAAHALDH1A1HPGDHSP90AA1LMNA | |
| Ammonia Solution, Strong SCHEMBL28872308 | 0.75 | PRKCA (0.42) | FAAHALDH1A1HPGDHSP90AA1LMNA | |
| SCHEMBL20621984 | 0.74 | PTGS1 (0.58) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL8192444 | 0.73 | LMNA (0.39) | FAAHALDH1A1HPGDHSP90AA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240410900-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | claimed |
| EP-4388014-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2024-06-26 | — | — | EP | claimed |
| CN-117858905-A | Multivalent anti-variant FC region antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2023021055-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-02-23 | — | — | WO | claimed |
| EP-1961767-B1 | Diagnosis and treatment of cancers and other conditions | BIOSCEPTRE INT LTD (AU) | 2012-03-07 | — | — | EP | claimed |
| US-20110092674-A1 | Non-Functional P2X7 Receptor | INTREAT PTY LIMITED (AU) | 2011-04-21 | — | — | US | claimed |
| US-20040142342-A1 | Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions | INTREAT PTY LIMITED (AU) | 2004-07-22 | — | — | US | claimed |
| EP-1360203-A1 | ANTIBODIES TO NON-FUNCTIONAL P 2 X 7 RECEPTOR DIAGNOSIS AND TREATMENT OF CANCERS AND OTHER CONDITIONS | Intreat Pty Limited (AU) | 2003-11-12 | — | — | EP | claimed |
| WO-2003020762-A1 | ANTIBODIES TO NON-FUNCTIONAL P2X7RECEPTOR, DIAGNOSIS AND TREATMENT OF CANCERS AND OTHER CONDITIONS | INTREAT PTY LIMITED (AU) | 2003-03-13 | — | — | WO | claimed |
| WO-2002057306-A1 | ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR DIAGNOSIS AND TREATMENT OF CANCERS AND OTHER CONDITIONS | INTREAT PTY LIMITED (AU) | 2002-07-25 | — | — | WO | claimed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| US-6235886-B1 | OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0595863-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1994-05-11 | — | — | EP | claimed |
| WO-1993000935-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-01-21 | — | — | WO | claimed |
| WO-2026097136-A1 | IMMUNOGENIC COMPOSITION FOR PREVENTING OR TREATING GROUP A STREPTOCOCCUS INFECTION | GRIFFITH UNIVERSITY (AU) | 2026-05-15 | — | — | WO | disclosed |
| US-20240410900-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-0347959-A1 | Antibodies against fibrin, immunogen used in their preparation, process for determining fibrin and pharmaceutical preparation based on the antibodies | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1989-12-27 | — | — | EP | disclosed |
| EP-0344578-A1 | Method to determine an immunologically detectable substance, and suitable reaction vial for this | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | disclosed |
| EP-0329994-A1 | Immunogen and its use in preparing antibodies to haemoglobin A1C | Roche Diagnostics GmbH (DE) | 1989-08-30 | — | — | EP | disclosed |